Sotac Pharmaceuticals Ltd
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
- Market Cap ₹ 131 Cr.
- Current Price ₹ 119
- High / Low ₹ 203 / 87.1
- Stock P/E 26.3
- Book Value ₹ 45.6
- Dividend Yield 0.00 %
- ROCE 19.3 %
- ROE 16.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 84.9 to 120 days.
- Working capital days have increased from 71.6 days to 161 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
23.41 | 28.68 | 43.44 | 73.15 | 57.98 | 67.11 | 64.60 | |
21.46 | 26.70 | 40.58 | 65.13 | 49.73 | 57.15 | 55.97 | |
Operating Profit | 1.95 | 1.98 | 2.86 | 8.02 | 8.25 | 9.96 | 8.63 |
OPM % | 8.33% | 6.90% | 6.58% | 10.96% | 14.23% | 14.84% | 13.36% |
0.34 | 0.69 | 0.35 | -1.63 | 0.24 | 1.32 | 1.72 | |
Interest | 0.49 | 0.37 | 0.61 | 0.58 | 0.90 | 1.01 | 0.98 |
Depreciation | 1.04 | 1.07 | 1.11 | 1.13 | 1.63 | 2.51 | 2.61 |
Profit before tax | 0.76 | 1.23 | 1.49 | 4.68 | 5.96 | 7.76 | 6.76 |
Tax % | 0.00% | 0.00% | 0.00% | 29.91% | 24.66% | 25.90% | |
0.76 | 1.23 | 1.48 | 3.30 | 4.50 | 5.75 | 4.99 | |
EPS in Rs | 8.00 | 5.35 | 6.43 | 14.35 | 5.59 | 5.20 | 4.52 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 13.94% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | 16% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 50% |
3 Years: | 57% |
TTM: | 17% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -3% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 29% |
3 Years: | 27% |
Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.95 | 2.30 | 2.30 | 2.30 | 8.05 | 11.05 | 11.05 |
Reserves | -0.04 | 1.40 | 2.51 | 4.80 | 12.94 | 37.22 | 39.33 |
8.11 | 7.24 | 6.68 | 7.39 | 10.66 | 11.17 | 10.49 | |
7.45 | 10.43 | 11.01 | 21.82 | 23.13 | 16.65 | 22.92 | |
Total Liabilities | 16.47 | 21.37 | 22.50 | 36.31 | 54.78 | 76.09 | 83.79 |
7.54 | 6.41 | 6.42 | 8.80 | 14.09 | 17.67 | 16.98 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.05 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 11.50 | 15.53 |
8.93 | 14.96 | 16.08 | 27.51 | 36.65 | 46.87 | 51.23 | |
Total Assets | 16.47 | 21.37 | 22.50 | 36.31 | 54.78 | 76.09 | 83.79 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
2.22 | 3.58 | 8.54 | -19.79 | |||
-1.07 | -3.28 | -10.93 | -12.53 | |||
-1.17 | -0.30 | 11.97 | 23.36 | |||
Net Cash Flow | -0.02 | 0.00 | 9.57 | -8.96 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 72.81 | 107.92 | 52.68 | 62.57 | 72.40 | 119.71 |
Inventory Days | 42.90 | 39.50 | 40.71 | 35.14 | 87.26 | 88.97 |
Days Payable | 140.53 | 175.52 | 112.49 | 128.97 | 165.78 | 119.08 |
Cash Conversion Cycle | -24.81 | -28.10 | -19.10 | -31.25 | -6.12 | 89.59 |
Working Capital Days | 19.65 | 31.18 | 26.97 | 29.09 | 24.93 | 160.94 |
ROCE % | 15.53% | 18.72% | 54.66% | 29.74% | 19.26% |
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
8 April 2025 - No demat/remat share requests for Q4 FY25.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
8 April 2025 - Exemption from filing corporate governance reports as per SEBI regulations.
-
Trading Window
28 March 2025 - Closure of trading window for insiders before financial results.
-
Trading Window-XBRL
28 March 2025 - SOTAC PHARMACEUTICALS LIMITED has informed about Closure of Trading Window
-
Appointment
26 March 2025 - Appointment of secretarial auditor for FY2024‑25
Business Overview:[1]
SPL specializes in manufacturing a broad range of pharmaceutical products across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins.